Poland· PL-100488471
Talvey
A other monoclonal antibodies and antibody drug conjugates product containing talquetamabum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Talquetamabum is registered in 5 of 19 countries.
Countries holding a registration under ATC L01FX (other monoclonal antibodies and antibody drug conjugates), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Talquetamabum · ATC L01FX
5 / 19 countries
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Talquetamabum
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- L01FX
- ATC class
- Other monoclonal antibodies and antibody drug conjugates
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05413868122510
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Talquetamabum in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTalvey 40 mg/mlJanssen-Cilag International
- SwitzerlandTalvey 40 mg/1.0 ml, InjektionslösungJanssen-Cilag AG
- CzechiaTALVEYJanssen-Cilag International N.V., Beerse
- SpainTALVEY 40 MG/ML SOLUCION INYECTABLEJanssen-Cilag International N.V
- IcelandTALVEYJanssen-Cilag International NV*
- NorwayTalveyJanssen-Cilag International N.V.
- SwedenTALVEY 40 mg/ml Injektionsvätska, lösningJanssen-Cilag International NV
- United StatesTALVEYJanssen Biotech, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Talvey
- Liechtenstein · Talvey
- Norway · Talvey
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2e4971f6-e4dd-4a3d-8168-5e4c4458b176 GET /v1/drugs/2e4971f6-e4dd-4a3d-8168-5e4c4458b176?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "40 mg/ml",
"packaging": "05413868122510 ¦ Rpz ¦ EU/1/23/1748/002 ¦ 151699\n1 fiol. 1 ml",
"substance": "Talquetamabum 40 mg/ml",
"common_name": "Talquetamabum",
"pl_product_id": "100488471",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about talquetamabum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.